7月27日，英派药业（07630）发布公告，宣布IMP3201被提名为临床前候选化合物（PCC），这是基于公司自主研发的双载荷ADC平台的首个成果。 IMP3201是一种靶向CEACAM5的双载荷ADC，采用优化的摩尔比搭载Exatecan及公司专有的ATR抑制剂。该化合物旨在治疗胃肠道恶性肿瘤，包括结直肠癌、胰腺癌、胃癌及食管鳞状细胞癌，以满足临床需求。（文章来源：财中社）
Source Link7月27日，英派药业（07630）发布公告，宣布IMP3201被提名为临床前候选化合物（PCC），这是基于公司自主研发的双载荷ADC平台的首个成果。 IMP3201是一种靶向CEACAM5的双载荷ADC，采用优化的摩尔比搭载Exatecan及公司专有的ATR抑制剂。该化合物旨在治疗胃肠道恶性肿瘤，包括结直肠癌、胰腺癌、胃癌及食管鳞状细胞癌，以满足临床需求。（文章来源：财中社）
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.